Docetaxel enhances the therapeutic efficacy of PSMA-specific CAR-T cells against prostate cancer models by suppressing MDSCs.
Xiaokang ZhangShishuo SunYangna MiaoYifan YuanWanxin ZhaoHailong LiXiaohuan WeiChao HuangXiaolei HuBixi WangHeng XuWei ZhangXiaoge GaoJingyuan SongJunnian ZhengQing ZhangPublished in: Journal of cancer research and clinical oncology (2022)
Cooperation of PSMA-specific CAR-T cells and the chemotherapy drug docetaxel can impressively ameliorate antitumor effectiveness against an installed metastatic human prostate cancer model in NPG mice.
Keyphrases
- prostate cancer
- pet ct
- radical prostatectomy
- locally advanced
- pet imaging
- induced apoptosis
- squamous cell carcinoma
- endothelial cells
- randomized controlled trial
- small cell lung cancer
- cell cycle arrest
- systematic review
- induced pluripotent stem cells
- high fat diet induced
- endoplasmic reticulum stress
- emergency department
- cell death
- metabolic syndrome
- computed tomography
- skeletal muscle
- adipose tissue
- drug induced
- adverse drug